MOESM2 of Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Li, H.; Zuraw, Bruce; Longhurst, Hilary; Cicardi, Marco; Bork, Konrad; Baker, James; Lumry, William; Bernstein, Jonathan; Manning, Michael; Levy, Donald; Riedl, Marc; Feuersenger, Henrike; Prusty, Subhransu; Pragst, Ingo; Machnig, Thomas; Craig, Timothy

doi:10.6084/m9.figshare.9746000.v1

13223_2019_362_MOESM2_ESM.docx (15.23 kB)

MOESM2 of Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

journal contribution

posted on 2019-08-29, 04:55 authored by H. Li, Bruce Zuraw, Hilary Longhurst, Marco Cicardi, Konrad Bork, James Baker, William Lumry, Jonathan Bernstein, Michael Manning, Donald Levy, Marc Riedl, Henrike Feuersenger, Subhransu Prusty, Ingo Pragst, Thomas Machnig, Timothy Craig

Additional file 2. COMPACT Study Committees, Investigators, and other Collaborators.

Funding

CSL Behring

History

Usage metrics

Keywords

C1-esterase inhibitor protein C1-INH (SC)COMPACT study HAEGARDAÂŽ Hereditary angioedema Long-term prophylaxis Replacement therapy Subcutaneous

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM2 of Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

Funding

CSL Behring

History

Usage metrics

Categories

Keywords

Licence

Exports